rokitamycin

Action and Spectrum

Actions and Spectrum: 

Actions: 

The macrolide antibiotic rokitamycin, which is efficient against Gram-positive bacteria, is sourced from Streptomyces kitasatoensis strains. By attaching itself specifically to the ribosome’s 50 S subunit, it inhibits the synthesis of proteins. Because eukaryotes lack 50S ribosomes, it is exclusive to prokaryotes alone. 

Spectrum: 

The properties of the macrolide rokitamycin, which has a 16-atom lactone ring and penetrates cells at a much higher concentration than other medications in its class, make it suitable for treating vaginal infections brought on by Mycoplasma or Chlamydia. 

The antimicrobial activity of the substance extends to Gram-positive bacteria such as Enterococcus faecius and Enterococcus faecalis, as well as H. influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, and Bacteroides fragilis. 

Drug Interaction

Adverse Reaction

Frequency not defined 

Blurred vision 

GI discomfort 

Episgastric pain 

Eoasinophillia 

Urticaria 

Vomiting 

Exanthema 

LFT abnormalities 

Nausea 

Skin rashes 

Black Box Warning

N/A

Contraindication / Caution

Contraindication/Caution: 

Contraindications 

• Hypersensitivity 

Cautions 

• Renal impairment 
• Hepatic impairment 
• Biliary occlusion 
• Drug interactions 
• Pregnancy  
• Breastfeeding 

Pregnancy / Lactation

Pregnancy consideration:  

No data is available regarding the administration of the drug during pregnancy. 

Breastfeeding warnings:  

No data is available regarding the excretion of drug in breast milk. 

Pregnancy category: 

Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester. 

Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. 

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.    

Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.    

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.    

Category N: No data is available for the drug under this category.

Pharmacology

Pharmacology: 

Rokitamycin, classified as a macrolide antibiotic, functions by disrupting bacterial protein synthesis. This process involves binding to the peptidyl transferase component situated on the 50S subunit of bacterial ribosomes.

Through this mechanism, rokitamycin inhibits the formation of peptide bonds during bacterial protein synthesis. Consequently, this interference impedes the growth and reproductive capabilities of bacteria. 

Pharmacodynamics: 

It attaches to the peptidyl transferase component within the 50S ribosomal subunit, preventing peptide bond formation and inhibiting bacterial protein synthesis. Its activity is directed against Gram-positive bacteria. 

Pharmacokinetics: 

Absorption 

The time to achieve peak effect is 0.5-1 hour 

Elimination and Excretion 

The half-life is 2-3 hours 

Adminstartion

Administration: 

The administration of rokitamycin involves taking the medication as directed by a healthcare professional. It is typically administered orally, and the recommended dosage and duration of treatment will be specified by the prescribing doctor.

Patient Information Leaflet

Patient information leaflet 

Generic Name: rokitamycin 

Pronounced: roh-kih-tuh-my-sin 

Why do we use rokitamycin? 

Rokitamycin, a macrolide antibiotic synthesized from strains of Streptomyces kitasatoensis, is utilized for its antimicrobial effects, particularly against Gram-positive bacteria. Its mechanism of action involves binding to the peptidyl transferase component of the 50S subunit of ribosomes, thereby inhibiting peptide bond formation and impeding bacterial protein synthesis.

The specificity of rokitamycin for prokaryotes arises from the absence of 50S ribosomes in eukaryotes. The application of rokitamycin is recommended in scenarios requiring the targeting of Gram-positive bacterial infections, rendering it a valuable asset in antibacterial therapy.